Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.
Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
The Alyssa Parian Lab works to identify early markers of dysplasia. We also study inflammatory bowel disease-associated cancers, conduct IBD clinical trials and examine IBD extraintestinal manifestations.
The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We’re working to identify the viral, host and immunologic factors that cause severe dengue illness.
Dr. Borahay's lab focuses on understanding pathobiology, developing novel treatments, and carrying out high quality clinical trials for common gynecologic problems with a special focus on uterine fibroids.
Dr. Braunstein's research focuses on inherited predisposition to hematologic diseases. His laboratory studies the inherited genetic changes in DNA that increase susceptibility to disease. Blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes are traditionally thought to be acquired disorders, however there is increasing evidence that inherited genetic changes play a role. In addition, Dr. Braunstein studies non-malignant blood diseases including atypical hemolytic uremic syndrome (aHUS) and related thrombotic disorders such as APLS, TTP and HELLP syndrome which are caused in part by genetic mutations. His work has identified a germline variants in the ERBB genes that predispose to hematologic malignancies. In addition, his research group found that patients with catastrophic APLS and HELLP syndrome frequently harbor germline mutations in complement regulatory genes. This has led directly to clinical trials designed to test the efficacy of complement inhibitio...n in patients with these disorders. Dr. Braunstein continues to work toward translating the scientific findings from the laboratory into improved care and treatment for patients. view more
Dr. Petty's laboratory interests focuses on antimicrobial chemotherapy, hospital-based medical practices, and internal medicine collaboration with ophthalmologic clinical trials.
Dr. Parikh's research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh's research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
His research is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, the development of clinical studies, and the design of clinical trials. Dr. Parikh's studies have refined the clinical definition in perioperative acute kidney in...jury and hepatorenal syndrome, developed strategies to reduce kidney discard in deceased donor transplantation, and advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh's research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and improve the outcomes in patients with kidney disease.
Dr. Parikh has also been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology.
view more
Dr. Ross and his research team have focused on Huntington's disease and Parkinson's disease, and now are using insights from these disorders to approach more complex diseases such as schizophrenia and bipolar disorder. They use biophysical and biochemical techniques, cell models, and transgenic mouse models to understand disease processes, and to provide targets for development of rational therapeutics. These then can provide a basis for developing small molecule interventions, which can be used both as probes to study biology, and if they have favorable drug-like properties, for potential therapeutic development. We have used two strategies for identifying lead compounds. The first is the traditional path of identification of specific molecular targets, such as enzymes like the LRRK2 kinase of Parkinson’s disease. Once structure is known, computational approaches or fragment based lead discovery, in collaboration, can be used. The second is to conduct phenotypic screens using ce...ll models, or in a collaboration, natural products in a yeast model. Once a lead compound is identified, we use cell models for initial tests of compounds, then generate analogs, and take compounds that look promising to preclinical therapeutic studies in animal models. The ultimate goal is to develop therapeutic strategies that can be brought to human clinical trials, and we have pioneered in developing biomarkers and genetic testing for developing strategies. view less
Dr. Clare Rock is an assistant Professor of Medicine, Division of Infectious Diseases at the Johns Hopkins University School of Medicine, Associate hospital Epidemiologist at the Johns Hopkins Hospital, and Faculty Member at Armstrong Institute for Patient Safety and Quality. Her research interest focuses the prevention of pathogen transmission in the hospital environment. This includes novel strategies of improving patient room cleaning and disinfection, including human factors engineering approaches, and conducting robust clinical trials to examine effectiveness of "no touch" novel technologies such as UV-C light. She has particular interest in carbapenem-resistant Enterobacteriaceae transmission in the hospital environment, including outbreak management, and transmission and epidemiology of Clostridium difficile. Her other area of interest is diagnostic stewardship, and the behavioral, cultural and human factors aspects of implementation of initiatives to enhance appropriate use of ...diagnostic tests. She leads a national initiative, as part of the High Value Practice Academic Alliance, examining strategies for appropriate testing for Clostridium difficile. This is a wider implementation of work that Dr. Rock conducted with The Johns Hopkins Health System facilities.
Dr. Rock has multiple sources of grant funding including from the Agency of Healthcare Research and Quality, Centers for Disease Control and Prevention, and industry. Dr. Rock is Vice Chair of the Society for Healthcare Epidemiology of America Research Network, and serves on the SHEA research committee. Dr. Rock earned her M.B.B.Ch. at the University College Dublin School of Medicine, National University of Ireland, and her MS masters of clinical science of research at the University of Maryland, where she received the MS scholar award for epidemiology. view more
Research in the Clifton O. Bingham III Lab focuses on defining clinical and biochemical disease phenotypes related to therapeutic responses in rheumatoid arthritis and osteoarthritis; developing rational clinical trial designs to test new treatments; improving patient-reported outcome measures; evaluating novel imaging modalities for arthritis; and examining the role of oral health in inflammatory arthritis.
The Dara Kraitchman Laboratory focuses on non-invasive imaging and minimally invasive treatment of cardiovascular disease. Our laboratory is actively involved in developing new methods to image myocardial function and perfusion using MRI. Current research interests are aimed at determining the optimal timing and method of the administration of mesenchymal stem cells to regenerate infarcted myocardium using non-invasive MR fluoroscopic delivery and imaging. MRI and radiolabeling techniques include novel MR and radiotracer stem cell labeling methods to determine the location, quantity and biodistribution of stem cells after delivery as well as to noninvasively determine the efficacy of these therapies in acute myocardial infarction and peripheral arterial disease.
Our other research focuses on the development of new animal models of human disease for noninvasive imaging studies and the development of promising new therapies in clinical trials for companion animals.
Areas of research in the David Shade Lab include data-management methods for clinical research, design and conduct of clinical trials, and internet usage for data acquisition and distribution.
The Douglas Ball Lab conducts clinical trials and pre-clinical laboratory studies of thyroid cancer. Our clinical trials, performed in collaboration with research staff in the upper aero-digestive group in the Sidney Kimmel Comprehensive Cancer Center, have included protocols for advanced radioiodine-refractory differentiated thyroid cancer and medullary thyroid cancer. Our pre-clinical research, conducted with Dr. Nelkin, Dr. Agrawal and other Kimmel Cancer Center researchers, includes pathogenesis and mechanisms of treatment resistance in medullary thyroid cancer, and pathogenesis and immune-directed therapy of anaplastic thyroid cancer.
Dr. Geetha’s team focuses on renal diseases in patients with systemic vasculitis as well as BK virus nephropathy in patients who have undergone renal transplant. Our studies include clinical trials on the effectiveness of rituximab versus cyclosporine in treating idiopathic membranous nephropathy and a multinational study of belimumab with azathioprine for maintaining remission of granulomatosis with polyangiitis and microscopic polyangiitis. We also have conducted research on the treatment of ANCA vasculitis, particularly in kidney transplant patients.
The goal of the lab's research is to identify molecular abnormalities that can improve the outcome of patients with pancreatic cancer and those at risk of developing this disease. Much of our work is focused on translational research evaluating markers and marker technologies that can help screen patients with an increased risk of developing pancreatic cancer.
Thus, marker efforts have been focused mostly on identifying markers of advanced precancerous neoplasia (PanINs and IPMNs) that could improve our ability to effectively screen patients at risk of developing pancreatic cancer. We lead or participate in a number of clinical research protocols involved in the screening and early detection of pancreatic neoplasia including the CAPS clinical trials. We maintain a large repository of specimens from cases and controls with and without pancreatic disease and use this repository to investigate candidate markers of pancreatic cancer for their utility to predict pancreatic cancer risk.
...
In addition, we have been working to identify familial pancreatic cancer susceptibility genes and identified BRCA2 as a pancreatic cancer susceptibility gene in 1996. We participate in the PACGENE consortium and the familial pancreatic cancer sequencing initiative. My lab also investigates pancreatic cancer genetics, epigenetics, molecular pathology, tumor stromal interactions and functional analysis of candidate genes and miRNAs. Dr. Goggins is the principal investigator of a phase I/II clinical trial evaluating the Parp inhibitor, olaparib along with irinotecan and cisplatin for patients with pancreatic cancer. view more
Research in the Grant (Xuguang) Tao Lab explores environmental and occupational epidemiology topics, including workers' compensation and injuries, and nosocomial infections. We conduct research through clinical trials and systematic literature reviews, and also use cancer registry data and GIS applications in environmental epidemiological research. Our recent studies have explored topics such as the effectiveness of lumbar epidural steroid injections following lumbar surgery, the effect of physician-dispensed medication on workers' compensation claim outcomes and how the use of opioid and psychotropic medications for workers' compensation claims impacts lost work time.
The Johns Hopkins Head and Neck Cancer Tissue Bank enrolls patients and collects research specimens from Head and Neck Tumor patients, both cancerous and benign, with particular focus on Head and Neck Squamous Cell Cancer patients. It provides specimens to researchers both within the institution and outside.
Principal Investigator
Department
The Brain Health Program is a multidisciplinary team of faculty from the departments of neurology, psychiatry, epidemiology, and radiology lead by Leah Rubin and Jennifer Coughlin. In the hope of revealing new directions for therapies, the group studies molecular biomarkers identified from tissue and brain imaging that are associated with memory problems related to HIV infection, aging, dementia, mental illness and traumatic brain injury. The team seeks to advance policies and practices to optimize brain health in vulnerable populations while destigmatizing these brain disorders.
Current and future projects include research on: the roles of the stress response, glucocorticoids, and inflammation in conditions that affect memory and the related factors that make people protected or or vulnerable to memory decline; new mobile apps that use iPads to improve our detection of memory deficits; clinical trials looking at short-term effects of low dose hydrocortisone and randomized to 28 day...s of treatment; imaging brain injury and repair in NFL players to guide players and the game; and the role of inflammation in memory deterioration in healthy aging, patients with HIV, and other neurodegenerative conditions. view more
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
